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The alveolar surface is covered by large flat Type I cells (alveolar epithelial cells 1, AEC1).
The normal physiological function of AEC1s involves gas exchange, based on their location
in approximation to the capillary endothelium and their thinness, and in ion and water flux,
as shown by the presence of solute active transport proteins, water channels, and imper-
meable tight junctions between cells. With the recent ability to produce relatively pure
cultures of AEC1 cells, new functions have been described.These may be relevant to lung
injury, repair, and the abnormal development that characterizes bronchopulmonary dyspla-
sia (BPD). To hypothesize a potential role for AEC1 in the development of lung injury and
abnormal repair/development in premature lungs, evidence is presented for their presence
in the developing lung, how their source may not be the Type II cell (AEC2) as has been
assumed for 40 years, and how the cell can be damaged by same type of stressors as
those which lead to BPD. Recent work shows that the cells are part of the innate immune
response, capable of producing pro-inflammatory mediators, which could contribute to the
increase in inflammation seen in early BPD. One of the receptors found exclusively on
AEC1 cells in the lung, called RAGE, may also have a role in increased inflammation and
alveolar simplification. While the current evidence for AEC1 involvement in BPD is circum-
stantial and limited at present, the accumulating data supports several hypotheses and
questions regarding potential differences in the behavior of AEC1 cells from newborn and
premature lung compared with the adult lung.
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INTRODUCTION
Bronchopulmonary dysplasia (BPD) is a common and serious
complication that affects up to 25% of infants born at<1500 g. In
fact, prematurity is the strongest risk factor for BPD (1). When the
premature lung is exposed to damage and stressors, from high
oxygen levels and/or mechanical ventilation and its associated
volutrauma, it can trigger a strong inflammatory response (2).
When this occurs during a vulnerable period of lung develop-
ment, prior to the alveolar stage (before 32–34 weeks gestation in
humans), there is an arrest of development leading to a decrease
in secondary septal formation and alveolarization. As a result,
the lungs of survivors of prematurity with BPD have relatively
simplified lungs, with decreased alveoli and surface area (3).
The story of research into the pathogenesis of BPD has followed
the larger story of biomedical research, moving from pathology
and physiology, to clinical risks and therapies and now an increas-
ing focus on the cellular and molecular reasons why the premature
lung is both so susceptible to damage, and why it reacts in the
way it does. For example, as outlined in a recent review (3), one
of the clinical risk factors, hyperoxia, promotes apoptosis, affects
the growth factors and other signals that are the developmen-
tal cross-talk between mesenchyme and epithelium that regulate
alveolarization (4).
There are over a dozen cell types in the lung parenchyma,
including fibroblasts, endothelial cells, dendritic cells, alveolar
macrophages, airway epithelial cells, Type II (AEC2), and Type I
epithelial cells (AEC1). Numerous studies have focused on each of
these cell types in relation to BPD. Of these, the AEC1 has perhaps
been the least examined, primarily because the cell was presumed
to be terminally differentiated, unable to proliferate and limited in
its potential responses to events like premature birth and injury.
This was reinforced by the difficulty of isolating and working with
AEC1 cells. As a result, there is limited understanding about the
cell in relation to any significant role it may play in BPD. The pur-
pose of this review is to bring together work done over the last
15 years that has deepened and expanded our appreciation of the
AEC1 cell, and how these findings point to a potential role in the
development of BPD. These roles are hypothesized and questions
generated to begin to address these hypotheses.
THE AEC1 CELL – GAS EXCHANGE AND ION/FLUID FLUX
Morphologically, the AEC1s are large, thin, and flat (Figure 1).
While they make up just over 10% of the cells within an alve-
olar unit in the normal adult human lung, compared with 18%
for the AEC2 cell, they cover 16 times the surface area (5). They
are situated in the lung in proximity to the capillary endothe-
lium, separated by either a shared basement membrane or a layer
of extracellular matrix. In approximately half of the lung surface
area, there is a very thin shared basement membrane structure,
and this is felt to be the most important site for gas exchange (6).
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FIGURE 1 | Schematic of the distal lung. From left to right: the cuboidal
AEC2 cell was the presumed source of new AEC1 cells. In at least 50% of
the lung, the AEC1 cell (green) shares a basement membrane (orange) with
the capillary endothelial cell (red), permitting the exchange of O2 and CO2 to
occur across them. The AEC1 cell is also involved in the movement of water
and ions. The ions move via a variety of channels. The tight junctions (black
bar) inhibit water movement between cells. Water does move into the AEC1
cell from the alveolar (upper) side through AQP5 channels. The AEC1 cells
express receptors capable of promoting an inflammatory response, including
TLR4 and RAGE. The T1α receptor, which localizes to the basal side of the
AEC1 cell, is probably used for anchoring the cell. It is specific for the AEC1
cell and often used to develop pure preparations of AEC1 cells for study.
The cells also function to help maintain ion and fluid balance
and control their flux at the air–liquid interface (7). Proper lung
function involves the alveolar lining fluid, which creates the air–
liquid interface. Evidence supports the critical role of the AECI cell
in the maintenance of the optimal amount of this fluid. First, the
tight junctions between the cells limit the overall movement of ions
and water (8). These junctions can be disrupted by stretch, which
could explain how barotrauma might lead to edema (9). Second,
the cell contains a number of ion transport channels, including
the amiloride-sensitive epithelial sodium channels (ENaC), CFTR
chloride channels, and a variety of potassium channels, which help
maintain the electrochemical gradient needed for ion movement
(10). Finally, one of the proteins used to characterize the Type I
cell is aquaporin-5 (AQP5). Depending on the species studied, it is
present in late gestation or early post natal life almost exclusively in
the AEC1 cell (11), and it is responsible for most of the water flow
across the lung epithelium (12). AQP5 mRNA levels rise acutely in
newborn mice exposed to hyperoxia and can remain elevated if the
rodents are returned to room air (13). This might help explain the
increase in lung water and decreased compliance seen in hyperoxic
premature lung injury (14).
ARE AEC1 CELLS PRESENT IN THE PREMATURE LUNG?
The purpose of this paper is to explore whether the AEC1 cell con-
tributes to BPD. As a first step, one must first show that AEC1 cells
are present at the appropriate time. In rodents, the large flat AEC1
begins to appear in the late canalicular period and increases in
number as the internal surface area increases during the saccular
and, especially, in the alveolar stage of mammalian lung develop-
ment. Until recently and based on morphology, it has generally
been felt that the cell appears at around the same time as the AEC2
alveolar epithelial cell, at least in mice and rats. There is some evi-
dence that this is under the control of the Wnt/b-catenin system
since absence of b-catenin in lung epithelium inhibits lung branch-
ing and respiratory epithelium differentiation and overexpression
causes epithelial hyperplasia (15). In vivo studies also support
roles for the transcription factors Fox2a and TTF-1 and C/EBPa in
terminal differentiation of respiratory epithelium. Recent reports
show that Hippo kinases upstream of Fox2a are also involved (16).
In contrast to rodents, studies in larger mammals such as sheep,
using electron microscopy to identify the AEC1 cells, indicate that
the cells are present far earlier in development (17). At 91 days
(term= 145–147 days), 4.8% of the cells appeared to be AEC1
cells. This was higher than the 1.2% of cells that were classified as
AEC2 cells. Furthermore, at 111 days, the proportion of AEC1 to
AEC2 cells was 63 and 4.3%, respectively.
It was only in the late 1990s that AEC1-specific cell proteins
were identified, and antibodies developed for these markers. These
markers were reviewed in 2003 (18). Two of the most prominent
are T1α, which is expressed in other tissues such as the kidney
and the brain but which, in the lung, is exclusively found in AEC1
cells, and RAGE, the receptor for advanced glycation end-products,
which is also found in many organs but only on AEC1 cells in
the lung.
T1α knockout mice that die at birth of respiratory failure, have
far fewer AEC1 cells, increased cell proliferation, and decreased
alveoli, indicating a role for T1α and for AEC1 in overall lung
development (19). T1α protein in whole lung homogenates is
low in rat lungs until just prior to delivery, which correlates to
the morphological appearance referred to above. However, by
immunohistochemistry, lung staining is visible in the tubules that
are just proximal to the developing distal end of the branches by
embryonic day 17, and only extends to the distal buds by embry-
onic day 20 (20). Whether the T1α positive cells seen before the
active increase in both T1α protein and AEC1 cell number are
the source of the AEC1 differentiation is not known. Information
regarding RAGE is outlined below.
WHERE DO AEC1 CELLS COME FROM?
Based on several lines of evidence, it has generally been held that
the AEC2 cell is the source of the AEC1 cell. First, in in vivo
injury models dating back to the early 1970s, there was a loss
of AEC1 cells, followed by a replenishment, but only AEC2 cells
showed signs of proliferation. Evans et al. demonstrated, more
than 40 years ago, that when lungs were exposed to NO2 and
the lung epithelium injured, it was the AEC2 cell that took up
tritiated thymidine, indicating cell division, while the remaining
AEC1s were quiescent and that the sister cells derived from the
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dividing AEC2 cell often became new AEC1 cells (21). Second,
when cultured on plastic, AEC2 cells become flattened and begin
to express proteins that are present in AEC1 cells but not in AEC2
cells, including T1α (22), AQP5 (23), and caveolin-1 (24). This
transdifferentiation is directed, in part, by switching from BMP-
predominant to TGF-β predominant signaling (25). Studies of
lineage-labeling AEC2 cells demonstrated that under conditions
of injury, AEC1 cells came from AEC2 parents (26). The inability
to demonstrate AEC1 cell proliferation led to the conclusion that
these cells were terminally differentiated and had lost their ability
to divide, so they must come from another source.
There are several observations and experiments, however,
which call this conclusion into question. As noted above, in elec-
tron microscopy studies in sheep fetuses, AEC1 cells are present
in larger proportion than AEC2 cells very early in gestation. In
another study in sheep, the same group of investigators showed
that expansion of lung volumes by tracheal occlusion in the fetus
increased the proportion of AEC1 cells from 63 to almost 90%
but that if the lung was then deflated, the proportion of AEC1
cells fell, while AEC2 cells increased. This was accompanied by the
increased appearance of what the authors termed an“intermediate
cell.” Along with hypothesizing that AEC1 cells have the capacity
to transdifferentiate to AEC2 cells, the authors proposed that this
intermediate cell, and not just AEC2 cells, may be a potential source
of both AECI and AEC2 cells (27).
The concept that there are lung cells that have the capacity
to become either AEC1 or AEC2 cells is strongly supported by
work summarized this year in a paper in Nature from Desai et al.
(28) in which they describe how, in mice, markers of AEC1 cells
appear 5 days before saccularization; how the expression pattern
of cell-specific markers (including T1α and RAGE for AEC1 and
surfactant protein C, Nkx2.1, and ABCA3 for AEC2 cells) is con-
sistent with a precursor cell that expresses some of each class of
markers before further differentiating; how the clonal expansion
of distal airway cells labeled at embryonic day 15.5 with green flu-
orescent protein (GFP) demonstrated the label in both cell types
in newborn and older mice; that no one has described the inter-
mediate cell between the AEC2 and the AEC1 in which one should
be able to see both the flattened morphology of the AEC1 cell type
along with residual lamellar bodies that mark the AEC2 cell (this,
in fact, is described in the fetal sheep (27)); how, when AEC2 cells
were labeled with GFP, the label did not appear in AEC1 cells. This
argues strongly that the normal source of AEC1 cells is not the
AEC2 cell but rather what they term a bipotent progenitor cell.
This progenitor cell itself may be an intermediate step, derived
from what looks morphologically like an alveolar epithelial stem
cell (17).
These authors also used AEC2 cell lineage-labeling to look at an
injury model and found that after hyperoxia in 2-month-old mice,
the number of labeled AEC1 cells went up significantly. This may
be why even recent reviews have maintained that AEC1 cells are
derived from AEC2 cells, i.e., the original studies involved injury
models (21).
DAMAGE TO AEC1 CELLS
BPD is precipitated by damage done by premature birth, volu-
trauma, and oxygen toxicity. How do AEC1 cells react to injury?
Because they cover so much of the surface of the lung,AEC1cells
are at risk for environmental injury. Bleomycin is a common
method to induce injury, both acute and chronic, in animal
models. Exposure initially denudes the lung of AEC1 cells and
leads to an overall loss of these cells in the subsequent fibrotic
lung (26).
Regarding hyperoxic injury, in 1968, Bowden et al. showed
that the AEC2 cell was relatively spared from hyperoxic injury
compared to AEC1 (29). In another study, using adult rats, 7–
14 days exposure to 85% oxygen did not affect the number of AEC1
cells, whereas the number of AEC2 cells was markedly increased.
However, by electron microscopy, the intracellular organelles such
as endoplasmic reticulum, Golgi apparatus, and mitochondria
within the AEC1 population were all hypertrophied, as if the cells
were geared up to produce in response to the high oxygen concen-
tration (30). It may be that AEC1 susceptibility to oxygen-induced
injury is species specific. When adult baboons were exposed to
100% oxygen, injury was first seen in endothelial cells followed by
AEC1 cells, which demonstrated a necrosis pattern (31). This is
similar to the in vitro effects of high oxygen on the lung adenocar-
cinoma cell line A549 (32). In contrast, in newborn mice, exposure
to 100% O2 increased the mRNA for T1α and AQP5, which are
AEC1-specific, implying that AEC1 cells did not die, but either
increased in number or turned on the expression of these genes
(13). Overall, these models demonstrate that AEC1 cells have the
capacity to respond to oxygen stress, but the type of response has
not been consistently observed.
Mechanical ventilation, primarily consisting of cyclic stretch-
ing from volume, is a second primary clinical association
with BPD. The direct relationship between stretch and AEC1
cells has not been well-studied, probably because of the dif-
ficulty in isolating and growing AEC1 cells in vitro. There is,
however, some indirect evidence for AEC1 responsiveness to
stretch.
Cyclic stretching of lung epithelial cells allowed to differentiate
to Type I phenotype in vitro caused an increase in their permeabil-
ity, and this was blocked by the addition of either an antioxidant
or an NF-κB activation inhibitor (33). Cyclic stretch of the lung
epithelial cell line A549, which has both AEC2 and AEC1 prop-
erties [for example, it expresses RAGE (34)] provoked increases
in pro-inflammatory cytokine production (35). In another study
of A549 cells, investigators demonstrated an increase in HMGB1
production and release (36). HMGB1 is a damage-associated mol-
ecule released by stressed and necrotic cells and can stimulate
inflammation (37).
The susceptibility of AEC1 cells to changes induced by stretch
may also be dependent on the (a) type of stretch or expansion
and (b) on the degree of prematurity. This is illustrated by the
studies of continuous static expansion in sheep. When done in the
fetus, the proportion of AEC1 cells went up markedly (27), but this
was not seen with high versus low PEEP ventilation in 2-week-old
lambs (38).
The evidence for AEC1 response to hyperoxia is stronger
than for volutrauma, which awaits more direct experimentation
on AEC1 cells, but taken together, it is very likely that AEC1
cells do respond to the type of stimuli most closely associated
with BPD.
www.frontiersin.org May 2014 | Volume 2 | Article 45 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rozycki Type I cells and BPD
INNATE IMMUNE FUNCTION
As noted, the earliest stages in the development of BPD are
associated with inflammation (2) (Figure 2). Until AEC1 cells
could be studied independently, their immune and inflammatory
functions were unknown. In 1988, Dobbs et al. described a protein,
which they called rTI40 that was specific for AEC1 cells (22). In
1995, Rishi et al. cloned the T1α gene and showed how, in the lung,
it was exclusively expressed in AEC1 cells (39), and it turned out
that rTI40 and T1α are the same. This led to the use of specific anti-
bodies to prepare highly enriched samples of AEC1 cells from rats
and mice. Freshly isolated AEC1 cells, it turned out, were differ-
ent from AEC1 cells derived from in vitro differentiation of AEC2
cells. They differ in their molecular phenotype (40). They have the
capacity to proliferate (41). A recent review provides details of the
many features that culture of AEC1 has revealed (42).
Among the newly revealed capacities of the AEC1s is an innate
immune effect. This is not surprising given that these cells have,
after the skin, the largest exposure to the environment. The cells
express toll-like receptor 4, which reacts to bacterial products and
produce cytokines such as TNF-α, IL-β, and IL-6 after exposure to
LPS both in vivo and in vitro (43). In fact, some authors believe
that the AEC1 cell is a more important source of pro-inflammatory
signaling than the AEC2 cell, which has traditionally been thought
of as the distal lung cell responder to noxious environmental
stimuli (44).
THE RAGE RECEPTOR
One potentially intriguing characteristic of the AEC1 is its expres-
sion of the RAGE, a member of the immunoglobulin superfamily
(Figure 2). RAGE is expressed on the surface of many cell types,but
the highest levels are found in the lung, specifically on the AEC1
(45). In rodents, limited amounts of RAGE are present before
E18.5, at which point the levels rise steadily, especially after P4
when the animal enters the alveolar phase (46). A note of cau-
tion must be added when looking at studies that compare RAGE
or any other AEC1 marker, between newborn and older animals,
especially rodents. These measures are usually normalized to total
protein or, in the case of mRNA, to a housekeeping gene, and are
derived from whole lung samples. Since the number of AEC1 cells
only begin to rise exponentially at the alveolar phase, the total
amount of the receptor might be low, but the relative amount of
the receptor to the cells capable of expressing it could be completely
different.
Investigators have described several aspects of the biology of
RAGE that potentially implicate it in the development of BPD in
newborn infants.
Aside from the glycation end-products which gave the recep-
tor its name, ligands for RAGE include damage-associate products,
including HMGB1 (47), which have been associated with BPD (48)
and, as noted above, is released from damaged lungs and A549 cells
(36).
Upon stimulation, RAGE signals are transduced through
MAPK and NF-κB pathways and promote a variety of cellu-
lar functions. Relevant to newborn lung disease, these functions
include the production of pro-inflammatory cytokines, as well as
apoptosis (49). Apoptosis is an important mechanism for hyper-
oxic lung epithelial injury (50). Reynolds et al. demonstrated that
adult RAGE-null mice survived longer and had diminished inflam-
mation and inflammatory signals after 4 days in 75% FiO2 (51),
implicating the RAGE receptor in pathways leading to hyperoxic
pulmonary injury.
After the initial inflammatory stage in BPD, there is inhibi-
tion of normal development, with decreased secondary septal
formation and decreased alveolar development. In both adult
and late fetal rats, overexpression of RAGE leads to simplification
of lung architecture, leading to a picture which resembles BPD
(49, 52). Conditional overexpression of RAGE in surfactant pro-
tein C expressing cells late in gestation decreased the number of
AEC1 cells and seemed to make their attachment to the basement
membrane far less secure (53).
FIGURE 2 | Schematic of some RAGE functions. From left to right:
engagement of the RAGE receptor with ligands such as HMGB1
activates intracellular pathways, including several MAPkinases, resulting
ultimately in activation of NF-κB. This, in turn, can promote the
expression and export of pro-inflammatory mediators. RAGE activation
has also been shown to inhibit apoptosis, both by decreasing FAS (CD95)
on the cell surface and by inhibiting p53. RAGE activation increases the
production of more RAGE. Soluble Rage (sRAGE) is a truncated variant of
whole RAGE, missing the transmembrane portion, which is snipped off
by a cell surface metallopeptidase, ADAM10. Once released, sRAGE can
bind to free RAGE ligands and make them unavailable to bind to
membrane-bound RAGE. In newborn animals exposed to LPS in utero, or
hyperoxia after birth the amount of soluble RAGE is diminished, which
would lead to less attachment of the sRAGE to the pro-inflammatory
ligands, making them more available to attach to pro-inflammatory
receptors like mRAGE at the left.
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It would, therefore be tempting to invoke a role for RAGE
in the pathophysiology of BPD, first in the inflammatory phase
and then in the developmental arrest/alveolar inhibition phase. It
must be noted, however, that some data raise questions about this
hypothesis.
Rats born to mothers who had received intramaniotic LPS (to
create chorioamnionitis) and who were then reared in hyperoxia
had more collagen and TGF-β but decreased RAGE mRNA and
sRAGE protein than controls (54). This is one among the number
of animal models of BPD and may not be the best, as the role of
chorioamnionitis in BPD has become controversial (55). On the
other hand, when newborn rats were exposed to 95% oxygen for
2 days, there was no effect on either membrane-bound or sRAGE.
Only after 8 days of hyperoxia was there a decrease in the soluble
form only, again for whole lung rather than relative to AEC cell
number (56).
One of the interesting and unique aspects of RAGE behavior,
and why it may be important to take into account what measure-
ments are being normalized to, is that rather than downregulating
expression, as often happens to receptors, engagement with its lig-
ands leads to increases in RAGE mRNA and protein levels. That
this does not lead to uncontrolled inflammation may be because
RAGE exists primarily in two forms, a transmembrane receptor
and a shorter soluble form, which is released locally and soaks up
ligands, making them unavailable for binding to the cell-associated
RAGE receptor. One study has examined lung sRAGE levels and
found them lower on the first day of life in premature infants
born to mothers with histological chorioamnionitis. The authors
speculated that its absence contributed to a pro- versus counter-
inflammatory imbalance that has been associated with BPD (57).
Thus, too much RAGE might interfere with lung development,
while too little, at least of the soluble form, might enhance the
inflammatory response.
HYPOTHETICAL ROLES FOR AEC1 CELLS IN BPD
Based on what has been outlined here, there are several ways in
which AEC1 cells might play a role in the development of BPD.
Perhaps most importantly, the cells are present and developing
(rapidly at the alveolar stage), so that perturbations could have sig-
nificant implications. It must be stated up front, however, that the
hypothesis that AEC1 cells are more sensitive to damage and that
they are preferentially lost, without having any secondary effects,
is certainly plausible, given the current state of the evidence.
a. The absence of AEC1 cells during development causes severe
disruption of lung development distally, at the terminal air sacs
(52). This means that their presence may be critical. Alveo-
lar development is controlled by signals that go back and forth
between the mesenchyme and the invading/growing epithelium
as well as between epithelial cell types (4). Since these cells are
among the most susceptible to injury, one can hypothesize that
damage to the AEC1 cells and/or their progenitors could inter-
fere with the signaling cross-talk, becoming one contributing
factor to the disruption of pulmonary development in BPD.
b. The early pro-inflammatory state of the premature lung that
eventually can be diagnosed as BPD is one area in which
AEC1 cells might be acting. The cells have the capacity to
produce several of the mediators that have been associated with
BPD, including TNF-α, IL-β, and IL-6 (43). They can produce
HMGB1, a ligand for RAGE. They, in fact, are the main, if
not sole, cell type expressing RAGE. To date, however, there
is no evidence that inflammatory mediators in either human
neonates or in animal models of BPD come from AEC1s, but
until recently it was not possible to study AEC1 cells alone.
There are as yet no studies yet examining how the innate
immune response in AEC1s might change over development,
by comparing cells from the pre-alveolar stage to ones in the
alveolar stage and from adult lungs.
c. The potential role of the RAGE receptor is also intriguing. Not
only can its activation promote inflammation but also too much
RAGE (which is meant to mimic too much RAGE activation)
can lead to the kind of simplified lung morphology seen in
established BPD (49, 52). This is what was seen in the studies
where RAGE expression was begun 2–3 days before delivery in
mice (49), coinciding with the saccular stage of lung develop-
ment. Infants who are exposed to oxygen and volutrauma at
this stage are at the highest risk for BPD.
There is, as yet, no evidence for any role for RAGE in BPD,
except indirectly, as one of its ligands, HMGB1, is elevated in the
lungs of babies who get BPD. HMGB1 can also bind to the toll-like
receptors 2 and 4 and trigger inflammatory mediator expression
so this observation is not conclusive.
On the other side of the coin, a decrease in RAGE, especially the
soluble form, might be a way by which RAGE contributes to lung
inflammation. Decreased sRAGE can lead to increased inflamma-
tion as stimuli become more available to bind to pro-inflammatory
receptors on alveolar macrophages, AEC2 cells, and AEC1s. The
observations about the rat chorioamnionitis/hyperoxia model
(54), and the prolonged newborn hyperoxia model (56), both of
which had decreased sRAGE, are consistent with this hypothesis.
Alternatively, this might again demonstrate an increased overall
loss of AEC1 cells and not have any direct effects.
SOME QUESTIONS RAISED
Using current techniques, up to 99% pure AEC1 cells can be iso-
lated from rat lungs (42). Applying and modifying these methods
to the newborn and even preterm animal can provide the means
to begin answering some of the questions raised by the hypotheses
in the previous section. Some of the early questions that might be
explored include:
a. Are newborn (pre-alveolar) rodent AEC1 cells more sensitive
to damage from hyperoxia?
b. Can AEC1 cells raised in culture react to cyclic stretch and does
this response differ in cells from younger animals?
c. Does the absence of AEC1 cells or of their progenitor cell cause
a similar pathology to BPD? Tying a conditional lethal gene to
RAGE or T1α expression could address this.
d. Do younger cells have an increased response to pro-
inflammatory stimuli such as LPS or HMGB1 in vitro?
e. Is there a difference between RAGE density on younger and
older AEC1 cells? Is there a difference in the RAGE response to
stimulation by age? Is there a difference in the release of sRAGE?
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There are, of course, other questions that can be asked leading to
other investigations. With the availability of established techniques
for acquiring AEC1 cells and the tantalizing but very incomplete
data reviewed here, this is a good time to put effort into studying
AEC1 cells and determining what contribution they make to the
development of BPD.
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